Hepatitis B Clinical Trial
Official title:
Comparison of the Efficacy and Safety of Entecavir Versus Adefovir in Subjects Chronically Infected With Hepatitis B Virus and Evidence of Hepatic Decompensation
Verified date | June 2013 |
Source | Bristol-Myers Squibb |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
This is a phase IIIb comparative study of entecavir 1.0 mg once daily (QD) vs. adefovir 10 mg QD in patients who have chronic hepatitis B infection and hepatic decompensation. The patients are treated for 96 weeks after the last subject is randomized.
Status | Completed |
Enrollment | 195 |
Est. completion date | May 2013 |
Est. primary completion date | October 2008 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 16 Years and older |
Eligibility |
Inclusion - Child-Pugh (CP) score >= 7 - Hepatitis B virus (HBV) viremia Exclusion - Alanine aminotransferase (ALT) > 15 x upper limit of normal (ULN) - Human immunodeficiency virus (HIV)/hepatitis C virus (HCV)/hepatitis D virus (HDV) coinfection |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Brazil | Local Institution | Porto Alegre - Rs | Rio Grande Do Sul |
Brazil | Local institution | Sao Paulo | |
Brazil | Local Institution | Sao Paulo | |
Brazil | Local Institution | Sao Paulo - Sp | Sao Paulo |
Canada | Local Institution | Calgary | Alberta |
Canada | Local Institution | Vancouver | British Columbia |
France | Local Institution | Clichy Cedex | |
France | Local Institution | Strasbourg | |
Greece | Local institution | Athens | |
Greece | Local Institution | Athens | |
Greece | Local Institution | Athens | |
Greece | Local Instituition | Thessaloniki | |
Greece | Local Institution | Thessaloniki | |
Hong Kong | Local Institution | Tai Po | |
India | Local Institution | Hyderabad | Andhra Pradesh |
India | Local Institution | Kolkata | |
India | Local Institution | Lucknow | |
India | Local Institution | New Delhi | |
Indonesia | Local Institution | Jakarta | |
Philippines | Local Institution | Cebu | |
Philippines | Local Institution | Manila | |
Poland | Local Institution | Bydgoszcz | |
Poland | Local Institution | Chorzow | |
Poland | Local Institution | Krakow | |
Poland | Local Institution | Lodz | |
Russian Federation | Local Institution | Moscow | |
Russian Federation | Local Institution | Moscow | |
Russian Federation | Local Institution | Smolensk | |
Singapore | Local Institution | Singapore | |
Singapore | Local Institution | Singapore | |
Singapore | Local Institution | Singapore | |
Singapore | Local Institution | Singapore | |
South Africa | Local Institution | Observatory | Western Cape |
South Africa | Local Institution | Paarl | Western Cape |
Taiwan | Local Institution | Changhua | |
Taiwan | Local Institution | Taichung | |
Taiwan | Local Institution | Taipei | |
Taiwan | Local Institution | Taoyuan | |
Taiwan | Local Institution | Tianan | |
Thailand | Local Institution | Bangkok | |
Thailand | Local Institution | Bangkok | |
Thailand | Local Institution | Hatyai | |
Turkey | Local Institution | Adana | |
Turkey | Local Institution | Izmir | |
United Kingdom | Local Institution | London | Greater London |
United States | Pediatric Gasteroenterology | Atlanta | Georgia |
United States | Johns Hopkins University | Baltimore | Maryland |
United States | Baylor University Medical Center | Dallas | Texas |
United States | Ut Southwestern Medical Center | Dallas | Texas |
United States | Henry Ford Health System Irb | Detroit | Michigan |
United States | Hawaii Medical Center East | Honolulu | Hawaii |
United States | Indiana University Med Center | Indianapolis | Indiana |
United States | The Cht Liver Research Center | Louisville | Kentucky |
United States | University Of Miami School Of Medicine | Miami | Florida |
United States | Yale University School Of Medicine | New Haven | Connecticut |
United States | Columbia Presbyterian Medical Center (Cpmc) | New York | New York |
United States | Mount Sinai Medical Center | New York | New York |
United States | Integris Baptist Medical Center | Oklahoma City | Oklahoma |
United States | Mcguire Dvamc | Richmond | Virginia |
United States | Research And Education, Inc. | San Diego | California |
United States | California Pacific Medical Center | San Francisco | California |
Lead Sponsor | Collaborator |
---|---|
Bristol-Myers Squibb |
United States, Brazil, Canada, France, Greece, Hong Kong, India, Indonesia, Philippines, Poland, Russian Federation, Singapore, South Africa, Taiwan, Thailand, Turkey, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change From Baseline in Hepatitis B Virus (HBV) DNA by Polymerase Chain Reaction (PCR) at Week 24 | Mean reduction in serum HBV DNA determined by PCR assay (log10 copies/mL) at Week 24 adjusted for baseline HBV DNA and lamivudine resistance (LVDr) status, based on linear regression analysis. | Baseline, Week 24 | No |
Secondary | Change From Baseline in HBV DNA by PCR at Week 48 | Mean change from baseline in HBV DNA by PCR at Week 48, adjusted for baseline HBV DNA and LVDr Status. | Baseline, Week 48 | No |
Secondary | Number of Participants With HBV DNA < 300 Copies/mL by PCR At Week 24 | Week 24 | No | |
Secondary | Number of Participants With HBV DNA < 300 Copies/mL by PCR At Week 48 | Week 48 | No | |
Secondary | Number of Participants Achieving Alanine Transaminase (ALT) Normalization (=1.0 x Upper Limit of Normal [ULN]) at Weeks 24 and 48 | Number of participants in each group who achieved ALT normalization (=1.0 x upper limit of normal [ULN]) among those with baseline ALT >1.0 x ULN at Weeks 24 and 48 | Week 24, Week 48 | No |
Secondary | Number of Subjects Achieving Composite Endpoint (HBV DNA < 10*4 Copies/mL by PCR Assay and Normal ALT [= 1.0 x ULN]) Through Week 48 | Baseline, Week 4, Week 8, Week 12, Week 24, Week 48 | No | |
Secondary | >=2-Point Reduction From Baseline in Child-Pugh Score Through Week 48 | Child-Pugh classification assesses the prognosis of chronic liver disease by 5 clinical measures, scored 1-3 each (most severe derangement=3). Score range: 5 (best prognosis) to 15 (worst prognosis). | Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48 | No |
Secondary | Number of Participants With Improvement or No Worsening in Child-Pugh Score From Baseline to Week 48 | Number of participants in each group with improvement or no worsening in Child-Pugh score from baseline to Week 48 as measured by improvement or no worsening in Child-Pugh score. Child-Pugh classification assesses the prognosis of chronic liver disease by 5 clinical measures, scored 1-3 each (most severe derangement=3). Score range: 5 (best prognosis) to 15 (worst prognosis). | Baseline, Week 4, Week 8, Week 12, Week 24, Week 48 | No |
Secondary | Change From Baseline in Child-Pugh Score Through Week 48 | Mean change from baseline in Child-Pugh score through week 48. Child-Pugh classification assesses the prognosis of chronic liver disease by 5 clinical measures, scored 1-3 each (most severe derangement=3). Score range: 5 (best prognosis) to 15 (worst prognosis). | Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48 | No |
Secondary | Number of Participants With Improvement in Child-Pugh Class at Week 24 and Week 48 | Number of Participants in each group with improvement in Child-Pugh score from baseline to Week 48 as measured by improvement in Child-Pugh class. Improvement in Child-Pugh Class is defined as change from B to A or C to A. Evaluable subjects are subjects with Child-Pugh Class B or C at Baseline. Child-Pugh classification assesses the prognosis of chronic liver disease by 5 clinical measures, scored 1-3 each (most severe derangement=3). Score range: 5 (best prognosis) to 15 (worst prognosis). Child-Pugh class A to C employs the added score from above: 5-6=Class A; 7-9=Class B; 10-15=Class C. | Week 24, Week 48 | No |
Secondary | Mean Change From Baseline in Model for End-Stage Liver Disease (MELD) Scores From Baseline Through Week 48 | Adjusted mean change from baseline in MELD score through Week 48 (adjusted for baseline value). The Model for End-Stage Liver Disease (MELD), is a scoring system for assessing the severity of chronic liver disease. MELD uses the patient's values for serum bilirubin, serum creatinine, and the international normalized ratio for prothrombin time (INR) to predict survival. In interpreting the MELD Score in hospitalized patients, the 3 month mortality is: 40 or more=100% mortality; 30-39=83% mortality; 20-29=76% mortality; 10-19=27% mortality; <10=4% mortality. | Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48 | No |
Secondary | Improvement or No Worsening in MELD Score Through Week 48 | Participants with improvement or no worsening (any decrease or no change from baseline in score) in MELD score through Week 48. The Model for End-Stage Liver Disease (MELD), is a scoring system for assessing the severity of chronic liver disease. MELD uses the patient's values for serum bilirubin, serum creatinine, and the international normalized ratio for prothrombin time (INR) to predict survival. In interpreting the MELD Score in hospitalized patients, the 3 month mortality is: 40 or more=100% mortality; 30-39=83% mortality; 20-29=76% mortality; 10-19=27% mortality; <10=4% mortality. | Baseline, Week 4, Week 8, Week 12, Week 24, Week 48 | No |
Secondary | Mean Changes From Baseline in Quality of Life as Measured by the Short Form 36 (SF-36) | Scoring for the SF-36 will be done using the algorithm developed by the Research ANd Development(RAND) Corporation (a scale of 0-100). Higher scores represent better quality of life. Coding for items with 2-category responses=0 and 100; 3-category=0/50/100; 5-category=0/25/50/75/100; 6-category=0/20/40/60/80/100. Scores of items in the same scale are combined to create the 8 scale scores (physical functioning, role-physical, bodily-pain, general health, vitality, social functioning, role-emotional, mental health). Physical and mental health composite scores will be computed for the group. | Baseline, Week 24, Week 48 | No |
Secondary | Mean Changes From Baseline in Quality of Life, as Measured by EuroQol-5D (EQ-5D) at Weeks 24 and 48 | The EQ-5D has 5 attributes (mobility, self-care, usual activity, pain/discomfort, and anxiety/depression), each with 3 levels (no problem, some problems, and major problems). This algorithm gives valuation (weights) to each of the 15 responses on the form. Each valuation is a negative number, subtracted from the maximum score of 1 (perfect well being). The overall health index score ranges from 0 (dead) to 1 (perfect health) value scale, and the visual analog scale ranges from 0 to 100. Item weights will be obtained from the EuroQol group. | Baseline, Week 24, Week 48 | No |
Secondary | Change From Baseline in Albumin Through Week 48 | Mean albumin levels, and mean change from baseline in albumin, a measure of synthetic liver function. Normal range for albumin = 3.5 - 5.3 g/dL. | Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48 | Yes |
Secondary | Mean Change From Baseline in Prothrombin Time Through Week 48 | Mean prothrombin time, and mean change from baseline in prothrombin time, a measure of synthetic liver function. Prothrombin time is the time it takes (in seconds) for a sample of blood to clot. Normal range for prothrombin time (PT) = 10-13 seconds. | Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48 | Yes |
Secondary | Mean Change From Baseline in Total Bilirubin Through Week 48 | Mean total bilirubin levels, and mean change from baseline in total bilirubin, a measure of liver secretory function.Normal range for total bilirubin = 0.2 - 1.2 mg/dL. | Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48 | Yes |
Secondary | Change From Baseline in Platelet Count Through Week 48 | Mean baseline platelet count and mean change from baseline in platelet count at specific timepoints. Platelets are the smallest particles found in the blood, which play a major role in forming blood clots. Normal range for platelets = 140 - 450 X 10*9 c/L. | Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48 | No |
Secondary | Participants Achieving Albumin Normalization Through Week 48 | Number of participants who achieved normalization of albumin (>= 1 x lower limit of normal [LLN]), a measure of liver function, at specific timepoints. | Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48 | No |
Secondary | Participants Achieving Prothrombin Time Normalization Through Week 48 | Number of participants who achieved normalization of prothrombin time (<= 1 x ULN), a measure of liver function, at specific timepoints. | Baseline, Week4, Week 8, Week 12, Week 24, Week 36, Week 48 | Yes |
Secondary | Participants Achieving Total Bilirubin Normalization Through Week 48 | Number of participants who achieved normalization of total bilirubin (<= 1 x ULN), a measure of liver function, at specific timepoints. | Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48 | No |
Secondary | Participants Achieving Platelet Count Normalization Through Week 48 | Number of participants who achieved normalization of platelet count (>= 1 x lower limit of normal [LLN]), a measure of liver function, at specific timepoints. | Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48 | Yes |
Secondary | Number of Hepatocellular Carcinoma (HCC) Events at Different Time Points Through Week 48 | HCC-free survival was analyzed using life tables. Measured values show the number of HCC events among treated participants at given time points. | Week 48 | Yes |
Secondary | Cumulative Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, HCC, Discontinuations Due to AEs, and Confirmed Creatinine Increase >=0.5 mg/dL | AE=any new untoward medical occurrence/worsening of a pre-existing medical condition regardless of causal relationship. SAE=any untoward medical occurrence at any dose that: results in death; is life-threatening; requires/prolongs inpatient hospitalization; results in persistent/significant disability; is cancer; is congenital anomaly/birth defect; results in drug dependency/abuse; is an important medical event. Grades:1=Mild, 2=Moderate, 3=Severe, 4=Life-threatening/disabling, 5=Death. Confirmed increase in serum creatinine=values =0.5 mg/dL compared with baseline on 2 sequential measures. | on-treatment events obtained after the start of therapy and no more than 5 days after the last dose of study therapy. | Yes |
Secondary | Number of Participants With Treatment-Emergent Grade 3/4 Laboratory Abnormalities - Week 48 and Cumulative Data | Grade 3/4 laboratory abnormalities (hematology, electrolyte, lipase, liver function, metabolic, renal function, urinalysis). The Week 48 data set was used to evaluate the Week-48 on-treatment safety. The cumulative data set was used to evaluate the safety while on treatment. Common Terminology Criteria for Adverse Events v3.0 (CTCAE) Grades:1=Mild, 2=Moderate, 3=Severe, 4=Life-threatening/disabling, 5=Death. | Week 48=all on-treatment laboratory measurements up to Week 48. Cumulative data = on-treatment laboratory measurements obtained after the start of therapy and no more than 5 days after the last dose of study therapy. | Yes |
Secondary | Number of Participants With Alanine Aminotransferase (ALT) Flares - On Treatment | ALT flare=ALT > 2 x baseline and > 10 x upper limit of normal (ULN) by clinical laboratory evaluation. Table includes number of participants with selected clinical events and/or laboratory abnormalities during ALT flares. Selected clinical events during ALT flares=ascites, hepatic encephalopathy, jaundice, bacterial peritonitis. Selected Laboratory abnormalities during ALT flares=international normalized ratio > 1.5 or prothrombin time >= 1.2 x ULN and total bilirubin >2.5 mg/dL and > 1 mg/dL increase from baseline. | On-treatment=up to Week 48 (Day 336); if discontinued early, all data up to 5 days after discontinuation date. | Yes |
Secondary | Number of Participants With Malignant Neoplasms - On Treatment or During 24-Week Follow-up Period | Data includes type of malignant neoplasm. | On-treatment=up to Week 48 (Day 336); if discontinued early, all data up to 5 days after discontinuation date. 24-week follow-up=limited to end-of-dosing values and those from 6 days after last dose of study therapy to end of follow-up. | Yes |
Secondary | Number of Participants Undergoing Liver Transplant - On-Treatment or 24-Week Follow-Up | On-treatment=up to Week 48 (Day 336); if discontinued early, all data up to 5 days after discontinuation date. 24-week follow-up=limited to end-of-dosing values and those from 6 days after last dose of study therapy to end of follow-up. | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01182311 -
Duration of Long-term Immunity After Hepatitis B Virus Immunization
|
||
Completed |
NCT04971928 -
Phase 1 Study of GSK3228836 Pharmacokinetics in Participants With Hepatic Impairment
|
Phase 1 | |
Completed |
NCT03285620 -
A Study of AL-034 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses in Healthy Participants
|
Phase 1 | |
Completed |
NCT01884415 -
Phase III, Study to Evaluate the Efficacy of Two Different HBV Vaccination Schemes in Patients With Hepatic Cirrhosis
|
Phase 3 | |
Recruiting |
NCT05404919 -
Utilization of Hepatitis B Virus NAT+ Donors for Hepatitis B Vaccinated Lung Transplant Candidates
|
Phase 2 | |
Completed |
NCT02153320 -
Study to Evaluate the Persistence of the Cellular and Humoral Immune Response Following Vaccinations With GlaxoSmithKline (GSK) Biologicals' Candidate Vaccines Containing HBsAg and Different Adjuvants in Healthy Adult Volunteers
|
Phase 1 | |
Completed |
NCT00352963 -
Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age).
|
Phase 3 | |
Completed |
NCT03567382 -
Arresting Vertical Transmission of Hepatitis B Virus
|
Phase 4 | |
Not yet recruiting |
NCT04056728 -
A Phase IV Study to Assess the Safety of EupentaTM Inj
|
Phase 4 | |
Not yet recruiting |
NCT03604016 -
Study to Assess Efficacy of Besifovir and L-carnitine in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver
|
Phase 4 | |
Completed |
NCT00753649 -
Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants
|
Phase 4 | |
Recruiting |
NCT03027258 -
Point-of-Delivery Prenatal Test Results Through mHealth to Improve Birth Outcome
|
N/A | |
Completed |
NCT02540538 -
Safety and Immunogenicity of HBAI20 Hepatitis B Vaccine in Naive Adults and Non-responders
|
Phase 1 | |
Terminated |
NCT02604199 -
A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection
|
Phase 2 | |
Completed |
NCT02421666 -
A Comparative Trial of Improving Care for Underserved Asian Americans Infected With HBV
|
N/A | |
Completed |
NCT02169674 -
Hepatitis B Booster Study in Adolescence
|
Phase 4 | |
Completed |
NCT01917357 -
A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject
|
Phase 3 | |
Completed |
NCT01368497 -
Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic Hepatitis B Virus (HBV) Infection
|
Phase 3 | |
Completed |
NCT01732354 -
Study for Consolidation Period of Chronic Hepatitis B
|
||
Recruiting |
NCT01462981 -
Cohort of Hepatitis B Research of Amsterdam
|
N/A |